CRISPR/Cas9 is hot. News of the revolutionary gene editing technique that is already shaking up bioscience has finally reached the news media and the public. Now comes a first rate example of how CRISPR is changing the pace ...
In the Age of Personalized Medicine, we've learned that one size doesn't fit all, least of all in cancer. Cancer is a disease of your cells, and sorting out your cancer from all others is a daunting challenge but one that ...
In rural Malawi, roughly 10 percent of the adult population has HIV. At the peak of the epidemic, in the 1990s and early 2000s, nearly everyone knew someone infected with or affected by the virus, what demographer Hans-Peter ...
Young children who are underweight experienced greater weight recovery the earlier an intervention was started, and the recovery was more significant in children with multiple household risk factors, according to a study ...
Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health ...
A new study of fat levels in oocytes (immature ova or eggs) has the potential to transform IVF practice, benefiting the dairy industry, and women seeking assisted reproductive treatment too.
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two ...
Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) ...